Nike Stock Slides as Revenue Miss Clouds Turnaround 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Bank of America Sees EUR/USD at 1.15 by Year-End 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
Disney Plans TV Restructuring With Hundreds of Layoffs 
WordPress Malware Uses Ethereum to Evade Removal 
Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
Malaysia Aviation Group to Buy Airbus SAE Unit 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
Add as a preferred source on Google
PLANO, Texas, March 01, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Management will also be available for one-on-one meetings at the conference.
Event: Cowen and Company 37th Annual Health Care Conference
Date: Wednesday, March 8, 2017
Time: 8:40 am ET
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
